Structural modification of DNA--a therapeutic option in SLE?

Frese, Steffen; Diamond, Betty (2011). Structural modification of DNA--a therapeutic option in SLE? Nature reviews - rheumatology, 7(12), pp. 733-8. New York, N.Y.: Nature Publishing Group 10.1038/nrrheum.2011.153

Full text not available from this repository.

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs, with glomerulonephritis representing a frequent and serious manifestation. SLE is characterized by the presence of various autoantibodies, including anti-DNA antibodies that occur in approximately 70% of patients with SLE and which contribute to disease pathogenesis. Consequently, immunosuppressive therapies are applied in the treatment of SLE to reduce autoantibody levels. However, increasing evidence suggests that DNA--especially double--stranded DNA-constitutes an important pathogenic factor that is able to activate inflammatory responses by itself in autoimmune diseases. Therefore, modifying the structure of DNA to reduce its pathogenicity might be a more targeted approach for the treatment of SLE than immunosuppression. This article presents information in support of this strategy, and discusses the potential methods of DNA structure manipulation--in light of data obtained from mouse models of SLE--including topoisomerase I inhibition, administration of DNase I, or modification of histones using heparin or histone deacetylase inhibitors.

Item Type:	Journal Article (Further Contribution)
Division/Institute:	04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Thoracic Surgery
UniBE Contributor:	Frese, Steffen R.
ISSN:	1759-4790
Publisher:	Nature Publishing Group
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:24
Last Modified:	05 Dec 2022 14:07
Publisher DOI:	10.1038/nrrheum.2011.153
PubMed ID:	22009329
Web of Science ID:	000298147300008
URI:	https://boris.unibe.ch/id/eprint/8743 (FactScience: 214373)